Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.59 USD
+0.02 (0.36%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.58 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Alimera Sciences, Inc. [ALIM]
Reports for Purchase
Showing records 41 - 60 ( 98 total )
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy; Raising Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Approved for Posterior Uveitis in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Reimbursement Secured in France; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy and Raise Price Target to $2.75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Record Revenues in 4Q18 and Full-Year 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
New Chief Executive Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien Secures Regulatory Approval in Canada; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preferred Stock Exchange Has No Effect on Earnings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien End User Demand Grew 12% YoY in 2Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien Reimbursement in UK May Expand to Phakic Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Microcaps Outperforming as Major Microcap Conference Approaches
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: SINE B
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Financial Results Reported; Reiterate Buy and Lowering Price Target to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
European Submission for Posterior Uveitis Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Positive USER Study Data Presented; 3Q17 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Preview of 3Q17 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien Distribution to Start in France; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
End User Unit Demand Continued to Grow in 2Q17; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
End User Unit Demand Continued to Grow in 2Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.